651324-06-0

Basic information

• Product Name: 1-Cyclohexene-1-carboxylic acid, 4-[(1,1-dimethylethyl)amino]-5-(di-2-propenylamino)-3-(1-ethylpropoxy)- , ethyl ester, (3R,4R,5S)-
• CAS NO: 651324-06-0
• Molecular Formula: C24H42N2O3
• Molecular Weight: 406.609
• Mol File: 651324-06-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 479.9±45.0 °C(Predicted)
• Density: 0.98±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 1-Cyclohexene-1-carboxylic acid, 4-[(1,1-dimethylethyl)amino]-5-(di-2-propenylamino)-3-(1-ethylpropoxy)- , ethyl ester, (3R,4R,5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cyclohexene-1-carboxylic acid, 4-[(1,1-dimethylethyl)amino]-5-(di-2-propenylamino)-3-(1-ethylpropoxy)- , ethyl ester, (3R,4R,5S)-(651324-06-0)
• EPA Substance Registry System: 1-Cyclohexene-1-carboxylic acid, 4-[(1,1-dimethylethyl)amino]-5-(di-2-propenylamino)-3-(1-ethylpropoxy)- , ethyl ester, (3R,4R,5S)-(651324-06-0)

Safety Data

• Hazardous Substances Data: 651324-06-0(Hazardous Substances Data)

Usage

General Description

The chemical "1-Cyclohexene-1-carboxylic acid, 4-[(1,1-dimethylethyl)amino]-5-(di-2-propenylamino)-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-" is a complex organic compound with a cyclohexene carboxylic acid core, as well as a tert-butylamine, di-2-propenylamino, and 1-ethylpropoxy side chains. The compound also contains an ethyl ester group, and is in the (3R,4R,5S) stereochemical configuration. This chemical is likely to have various applications in the pharmaceutical and chemical industries, given its intricate structure and potential for interactions with biological systems.

Upstream product

• 651324-05-9 ethyl (3R,4S,5R)-4,5-(1,1-Dimethylethyl)imino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate 
• 124-02-7 diallylamine 
• 651324-04-8 (3R,4S,5R)-[5-(tert-butylamino)-4-hydroxy-3-(pent-3-yloxy)]cyclohex-1-ene-1-carboxylic acid ethyl ester 
• 204254-96-6 (1S,5R,6S)-5-(pentan-3-yloxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylic acid ethyl ester 

Downstream Products

• 204255-11-8 oseltamivir phosphate 
• 196618-13-0 oseltamivir 
• 651324-07-1 ethyl (3R,4R,5S)-4-N-acetyl(1,1-dimethylethyl)amino-5-N,N-diallylamino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate 

Relevant articles and documents

Method for preparing antiviral drug oseltamivir phosphate intermediate tert-butylamine derivative I

The invention discloses a method for preparing a tert-butylamine derivative, and relates to the field of drug synthesis. The method comprises the following steps: 1, preparing a magnesium-amine compound, namely, adding magnesium halide and tert-butylamine A into an aprotic solvent, and carrying out a mixing stirring reaction for 0.5-1.5 h at a temperature of 0-15 DEG C to prepare a mixed solutionA; 2, adding a compound B into the mixed solution A prepared in the step 1, and carrying out a stirring reaction for more than 8 hours to prepare a mixed solution B; and 3, supplementing tert-butylamine D into the mixed solution B prepared in the step 2, and carrying out a stirring reaction for 24-48h at a temperature of 50-70 DEG C to prepare a tert-butylamine derivative I. By controlling the preparation temperature of the compound, the addition mode of tert-butylamine and the time of the ring-opening reaction, the curing phenomenon in the reaction and the increase of by-products can be effectively controlled.

The synthetic development of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu): A challenge for synthesis & process research

The evolution of the synthesis of oseltamivir phosphate (Tamiflu), used for the oral treatment and prevention of influenza virus infections (viral flu) is described. Oseltamivir phosphate is the ethyl ester prodrug of the corresponding acid, a potent and selective inhibitor of influenza neuraminidase. The discovery chemistry route and scalable routes used for kilo laboratory production as well as the technical access to oseltamivir phosphate from (-)-shikimic acid proceeding via a synthetically well-developed epoxide building block followed by azide transformations are reviewed. Synthesis and process research investigations towards azide-free conversions of the key epoxide building block to oseltamivir phosphate are discussed. The search for new routes to oseltamivir phosphate independent of shikimic acid including Diels-Alder approaches and transformations of aromatic rings employing a desymmetrization concept are presented in view of large-scale production requirements.